FT Options’s Altamira Therapeutics Ltd CYTO Stock Holding History

FT Options’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Hold	0	–	-$4K	–	462
2016 Q2	–	Hold	0	–	–	–	312

Other funds holding CYTO

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FT Options's CYTO Position: Q3 2016 in Review

FT Options sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2016, closing a stake of 1 share — an estimated $205K sold.

FT Options first reported a position in CYTO in Q2 2016 and held it in 1 quarter. The position peaked at $205K in Q2 2016. 3 funds tracked by Wall St. Rank hold CYTO as of Q3 2016.

FT Options reported no remaining Altamira Therapeutics Ltd position as of Q3 2016 after selling out during the quarter.
FT Options sold 1 Altamira Therapeutics Ltd share in Q3 2016, an estimated $205K.
FT Options first reported a position in Altamira Therapeutics Ltd in Q2 2016 and held it in 1 quarter.
FT Options's Altamira Therapeutics Ltd position peaked at $205K in Q2 2016.
3 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.